Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUST: mFOLFOXIRI + Cetuximab vs Bevacizumab for CRLM
NCT04687631Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2021
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of KL-140, bevacizumab in colorectal cancer (CRC), liver metastasis, sponsored by Fudan University. Started Jan 2021; status: recruiting.
02
Drugs
KL-140bevacizumab
03
Conditions
colorectal cancer (CRC)liver metastasis
Beyond the preview
Go deeper on NCT04687631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04687631.